Evidence map›Paper›PMID 40243636›Full record

ArticleInternational journal of molecular sciences2025

PD-L1

Mustafa Talib, Balázs Gyebrovszki, Anna Fodor, Anna Mészáros, Kata Balog Virág, Leila Gloria Barta, Bernadette Rojkovich, György Nagy, Gabriella Sármay

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mustafa TalibDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.ORCID 0000-0002-0721-4314
Balázs GyebrovszkiDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.ORCID 0000-0002-3809-6541
Anna FodorDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.ORCID 0009-0009-6506-6864
Anna MészárosDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.
Kata Balog VirágDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.ORCID 0000-0002-2291-0705
Leila Gloria BartaDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.
Bernadette RojkovichRheumatology-Rehabilitation Department, Buda Hospital of the Hospitaller Order of Saint John of God, 1027 Budapest, Hungary.
György NagyDepartment of Rheumatology and Immunology, Semmelweis University, 1023 Budapest, Hungary.
Gabriella SármayDepartment of Immunology, Eötvös Loránd University, 1053 Budapest, Hungary.

Funding

National Research, Development, and Innovation Office K 128546, 2018
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease. The pathomechanism of RA depends on both B and T cells. Regulatory B cells (Breg) have been shown to suppress T-cell immune responses and play a key role in modulating autoimmune processes. We aimed to investigate the possibility of utilizing PD-L1

Indexed as

Arthritis, RheumatoidB7-H1 AntigenB-Lymphocytes, RegulatoryInterferon-gammaInterleukinsAdultAgedCase-Control StudiesFemaleHumansInterleukin-21MaleMiddle AgedT-Lymphocytes, RegulatoryB7-H1 AntigenCD274 protein, humanInterferon-gammaInterleukin-21Interleukinshelper T cellsIFNΥIL-21PD1PD-L1regulatory B cellsrheumatoid arthritis

Identifiers

PMID40243636
PMCPMC11988511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.